The in-depth understanding of non-Hodgkin lymphoma (NHL) has become a major challenge, and many advances have been made since the introduction of the WHO classification in 2001.
However, the risk of diagnostic errors remains high due to the great diversity of lymphomas. There are in fact more than 80 subtypes of NHL, some of which are rare and particularly complex to characterize.
The LymphoSign Test offers a refined and reliable solution for NHL subclassification. It is CE-IVD marked for in vitro diagnostic use, affirming compliance with European safety and performance requirements.
The LymphoSign test evaluates the degree of differentiation of tumor cells by analyzing the expression levels of more than 130 relevant genetic markers, based on ligation-dependent PCR (RT-MLPSeq) technology (Table 1).
Table 1: List of LymphoSign test markers
Using an AI model trained on a database of over 3,000 cases, the RT-MIS platform determines the most probable classification among 13 B- and T-cell NHL subtypes:
DLBCL—activated B-cell subtype
DLBCL—germinal center B-cell subtype
DLBCL—Primary mediastinal B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Angioimmunoblastic T-cell lymphoma
ALK-positive anaplastic large cell lymphoma (ALCL ALK+)
ALK-negative cytotoxic ALCL
ALK-negative Th2 ALCL
Adult T-cell leukemia/lymphoma
NK/T-cell lymphoma
The LymphoSign test uses a semi-quantitative method: RT-MLPSeq. The multi-step in vitro test simultaneously evaluates genetic markers (genes, mutations, chromosomal translocations, etc.) using pairs of specific oligo-nucleotide probes for each of them.
This in vitro test is associated to high-throughput sequencing that allows multiple samples and dozens of genes to be tested at the same time.
LymphoSign test represents a significant advancement in the precise molecular classification of NHL. Utilizing a novel RT-MLPSeq approach and AI-enhanced bioinformatics, the test streamlines the pathologist’s workflow, improves subtype resolution, and supports more informed clinical decision-making.
For comprehensive information and detailed insights into our offerings, we invite you to explore our brochure.
|
|
These products are medical devices. Please follow the instructions of the manufacturer. |
